GRAIL, Inc. Common Stock (GRALV)
GRAIL, Inc. Common Stock operates in the Medical - Diagnostics & Research industry of the Healthcare sector, headquartered in Menlo Park, CA, US. The stock last traded at $18.63, up 8.19% on the session, giving a market capitalisation of $579.4M. Its beta of 0.00 implies it has historically moved less than the broad market.
GRAIL, LLC is a biotechnology firm dedicated to pioneering solutions for the early identification of cancer. The company offers Galleri, a multi-cancer early detection screening test designed for healthy individuals aged 50 and above who show no symptoms. Additionally, it provides DAC, a diagnostic assistance tool aimed at accelerating the diagnostic process for patients with a clinical suspicion of cancer. Beyond initial detection and diagnosis, GRAIL is also engaged in developing tests for minimal residual disease (MRD) and other post-treatment monitoring applications. Established in 2015, the company originally operated as PSC15, Inc. before rebranding as GRAIL, LLC in January 2016. Headquartered in Menlo Park, California, GRAIL, LLC functions as a subsidiary of Illumina, Inc.
GRAIL, Inc. Common Stock is most often compared with the following Healthcare names: